Journey Medical (DERM)
(Delayed Data from NSDQ)
$7.27 USD
+0.22 (3.12%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $7.26 -0.01 (-0.14%) 6:50 PM ET
5-Strong Sell of 5 5
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DERM 7.27 +0.22(3.12%)
Will DERM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DERM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DERM
New Strong Sell Stocks for September 4th
Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue Estimates
DERM: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates
Other News for DERM
20 Day Moving Average Resistance appears for DERM after 1.67% move
20 Day Moving Average Resistance appears for DERM after 0.7% move
Is DERM primed for downward momentum? 20 Day Moving Average Resistance shows up after climbing 0.14%
DERM Fell Below 20 Day Moving Average on September 12
DERM Crossed Above 50 Day Moving Average on September 11